Memantin Stada (Memantine Hydrochloride)

Memantine works by binding to the NMDA‑type glutamate receptor as a non‑competitive antagonist. This blocks excessive calcium entry into neurons caused by overstimulation of glutamate, reducing excitotoxic damage and helping to preserve neuronal integrity in the brain areas affected by Alzheimer's disease.

The specific dose of Memantin Stada is determined by the prescribing clinician based on the patient’s clinical condition, age, renal function and other individual factors. Physicians typically start with a low dose and may titrate upward, but exact dosing instructions should always come from the treating healthcare professional.

Safety data for memantine in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Memantin Stada product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantin Stada belongs to the NMDA‑receptor antagonist class, whereas drugs such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and targets excitotoxic pathways, while the others mainly enhance cholinergic transmission and are often started earlier in the disease course.

Memantin Stada tablets should be stored at room temperature, below 25 °C, in their original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Memantin Stada is taken orally, usually as a whole tablet swallowed with water. It is not intended for crushing, chewing, or splitting unless specifically directed by a healthcare professional. The medication is generally taken once daily, but the exact schedule is set by the prescriber.

Serious adverse reactions, although rare, include seizures, severe allergic responses such as rash or swelling, cardiac arrhythmias, and hallucinations. Patients should seek immediate medical attention if they experience any of these symptoms while on therapy.

Memantin Stada is contraindicated in patients with known hypersensitivity to memantine or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑antagonist agents, as these conditions may increase the risk of adverse effects.